Comparative Pharmacology
Head-to-head clinical analysis: ACALABRUTINIB versus CALQUENCE.
Peer-Reviewed Evidence
Head-to-head clinical analysis: ACALABRUTINIB versus CALQUENCE.
ACALABRUTINIB vs CALQUENCE
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Acalabrutinib is a selective, irreversible inhibitor of Bruton tyrosine kinase. It forms a covalent bond with a cysteine residue in the active site, blocking B-cell receptor signaling and inhibiting malignant B-cell proliferation and survival.
Acalabrutinib is a selective, irreversible inhibitor of Bruton tyrosine kinase (BTK). BTK is a key signaling molecule in the B-cell antigen receptor (BCR) and cytokine receptor pathways. In B cells, BTK activation results in pathways necessary for B-cell proliferation, trafficking, chemotaxis, and adhesion. Acalabrutinib and its active metabolite, acalabrutinib M27, form a covalent bond with the cysteine residue in the BTK active site, leading to inhibition of BTK enzymatic activity and downstream signaling, thereby reducing malignant B-cell survival and proliferation.
100 mg orally every 12 hours.
100 mg orally twice daily.
None Documented
None Documented
Terminal elimination half-life is approximately 1 hour. Clinical context: short half-life supports twice-daily dosing, but BTK occupancy remains >90% over 12 hours due to irreversible binding.
Terminal elimination half-life is 8 hours at steady state, supporting twice-daily dosing.
Primarily hepatic metabolism (CYP3A4); fecal excretion accounts for approximately 86% (including 69% as metabolites, 17% as unchanged drug). Renal excretion is minimal (<1% unchanged).
Fecal (77%), renal (15% as unchanged drug and metabolites).
Category C
Category C
BTK Inhibitor
BTK Inhibitor